GIGAGEN

In News

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B - Contagion Live

Contagion Live - Nov 25, 2024

Innovating Biothreat Therapies: An Interview with Head of GigaGen - The Clinical Trial Vanguard

The Clinical Trial Vanguard - Oct 17, 2024

Grifols ponies up $80M for polyclonal antibody biotech GigaGen - Fierce Biotech

Fierce Biotech - Mar 10, 2021

GigaGen Expands Contract With US Department of Defense for Synthetic Antibody Treatments for Botulinum Neurotoxins - Infection Control Today

Infection Control Today - Nov 27, 2023

Recombinant polyclonal antibodies for viral diseases - drugdiscoverynews.com

drugdiscoverynews.com - Mar 25, 2024

GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment - Clinical Trials Arena

Clinical Trials Arena - Nov 20, 2024

GigaGen Doses First Patient in Phase 1 Trial of Recombinant - GlobeNewswire

GlobeNewswire - Nov 19, 2024

Unleashing the potential of lab-grown recombinant polyclonal antibodies - Drug Target Review

Drug Target Review - Jul 17, 2024

Phase 1 clinical trial cleared for HBV antibody GIGA-2339 - European AIDS Treatment Group

European AIDS Treatment Group - Aug 07, 2024

GigaGen's New Contract with BARDA for Polyclonal Antibody Development - Contagion Live

Contagion Live - Oct 04, 2024

Peninsula biotech reels in potential $135 million contract to be first line of treatment against bioterrorism - The Business Journals

The Business Journals - Oct 03, 2024

GigaGen Announces New Office Space in South San Francisco - PR Newswire

PR Newswire - Jan 23, 2018

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment